Israel’s Rosetta Genomics has received a US patent for its microRNA-based test for the primary tumor type in primary and metastatic (secondary) cancer. By identifying the origin of the tumor, physicians can select the best treatment options for the patient.

http://www.rosettagenomics.com/press-releases